Embla Medical: Q4 6% below, but Embla on strong footing - ABG

Q4 a tad soft at 5% organic growth and EBIT -6%
But the undelrying business appears in very good shape
Consensus unlikely to make major changes to estimates


Q4 in numbers

Embla delivered 5% organic groiwth in Q4 for revenues of USD 225m (-1% vs. ABG 228 ; -1% vs. Cons. 227). EBITDA (pre-items) came to $46.5m (-2% vs. ABG 47.6 ; -2% vs. Cons. 47.3) and reported EBIT was $31.9m (-6% vs. ABG 34 ; -6% vs. Cons. 34). Net profit came to $18.6 (-15% vs. ABG 22 ; -20% vs. Cons. 22.1). Free Cash Flow was strong at $34m in Q4 and Net Debt/EBITDA fell to 2.4x.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/embla_medical/Equity-research/2025/2/embla-medical---q4-6-below-but-embla-on-strong-footing/